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PAFa b s t r a c t
Cutaneous melanomas are often difficult to treat when diagnosed in advanced stages. Melanoma
cells adapt to survive in extreme environmental conditions and are among the tumors with larger
genomic instability. Here we discuss some intrinsic and extrinsic mechanisms of resistance of
melanoma cells to both conventional and target therapies, such as autophagy, adaptation to
endoplasmic reticulum stress, metabolic reprogramming, mechanisms of tumor repopulation and
the role of extracellular vesicles in this later phenomenon. These biological processes are potentially
targetable and thus provide a platform for research and discovery of new drugs for combination
therapy to manage melanoma patient treatment.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cutaneous melanoma is a challenging disease to treat due its
high metastatic potential and well documented chemoresistance.
The first melanoma treatment options were the alkylating agent
dacarbazine and cytokines such as interferon and interleukin, but
none of these drugs or the combination of them demonstrated sig-
nificant impact to improve melanoma patient survival [1]. The first
improvement in clinical responses of metastatic melanoma patient
was obtained in 2011 with vemurafenib, a BRAFV600 kinase inhi-
bitor [2]. More recently, US Food and Drug Administration (FDA)
approved ipilimumab, a monoclonal antibody directed to CTLA-4
T lymphocyte receptor, for the treatment of metastatic melanoma
patients who do not have BRAFV600 mutation. The last FDA
approved drug for melanoma treatment was announced even more
recently, pembrolizumab, a monoclonal antibody directed against
the inhibitory receptor PD-1 (programmed cell death-1), expressed
on the surface of activated T cells, which results in the activation of
T-cell-mediated immune responses against tumor cells [3].
These immunomodulatory antibodies, anti-CTLA4 as well as
anti-PD1 or anti-PDL1, hold great promise to successfully controlmelanoma, inducing a protective and a long lasting antitumor
response [4]. The clinical results indicate a new paradigm in bio-
therapies, namely the blockade of regulatory immune checkpoints,
with the advantage of generating a specific antitumor response.
Adverse effects include the unleash of autoimmune reactions.
Combination strategies targeting different molecules involved in
immune checkpoints had already been tested [5]. Individual cases
treated with both ipilimumab and pembrolizumab were reported
and suggest exacerbation of immune adverse reactions upon
treatment with these monoclonal antibodies, which are still
manageable clinically. Combination of ipilimumab with other
agents, such as bevacizumab (anti-VEGF) is also promising [6]. In
this latter case, anti-VEGF treatment seems not only a good
antiangiogenic strategy, but also a potential immunomodulatory
strategy, as it neutralizes VEGF, a pleotropic cytokine involved in
the maintenance of dendritic cells in an immature state. Despite
the evident interest in these novel biotherapies, it is still not clear
how redundant are the several molecular pathways involved and
which cases will indeed benefit from the combination strategies
[5]. The cost of these approaches is still prohibitive for middle
and low income countries.
The therapeutic effects of other FDA approved drugs to treat
melanomas are often short-lived with high rates of tumor recur-
rence. Considering the high metastatic potential of melanoma,
the great challenge in the treatment of this disease is to make
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melanoma cells are highly adapted to unfavorable microenviron-
ment conditions, which favor the emergence of resistant cells. Here
we will discuss adaptive mechanisms adopted by melanoma cells
to guarantee tumor cell survival and proliferation. Melanoma cells
take advantage of survival pathways mediated by autophagy and
ER stress, and several pieces of evidence support the importance
of these pathways in melanoma development and chemoresis-
tance. Both autophagy and ER stress play dual role in cancer, being
tumor suppressor or promoting tumor growth, dependent on the
cellular context.
Adaptive mechanisms can induce melanoma dependence
towards some pathways that have cell survival as an outcome.
Comprehensive analysis of melanocyte malignant transformation
into melanomas indicated, for example, that melanoma cells tend
to produce higher amounts of reactive oxygen species (ROS) than
their parental melanocytes [7]. In a vicious cycle, excessive ROS
production favors mutations and accelerates melanoma progres-
sion. Accordingly, melanomas accumulate large number of geno-
mic mutations than any other human tumor [8]. Interfering in
such pathways constitute a potential therapeutic strategy to treat
or even prevent melanomas [9,10]. To exploit vulnerabilities in
the intracellular signaling pathways of melanoma cells is one
strategy for the development of new drugs. Here, we will revisit
mechanisms that may generate vulnerability, illustrating
potentially targetable mechanisms of both intrinsic (melanoma
cell-dependent) and extrinsic (microenvironment-dependent)
chemoresistance.
2. Intrinsic adaptive mechanisms of melanoma towards
chemoresistance
2.1. Autophagy
One of the adaptive mechanisms induced in melanoma cells is
autophagy. The emerging role of macro-autophagy, hereafter
called autophagy, in tumorigenesis is a current subject of research.
Autophagy is a catabolic process whereby cellular proteins and
organelles are degraded and recycled to sustain cellular metabo-
lism and homeostasis. However, autophagy seems to have a dual
role in tumors. Paradoxically, autophagy suppresses cancer
initiation [11] and promotes tumor progression. This dual role of
autophagy is based on the inhibition and activation of this
catabolic process by many oncogenes and tumor suppressors,
respectively [12]. Autophagy acts as a tumor suppressor at early
stages removing damaged organelles/proteins, thus reducing
potential sources of genomic instability. Whereas, during
tumor progression, autophagy favors tumor growth by
maintaining cellular energy levels during environment stress
conditions, including nutrient deprivation and exposure to
anticancer drugs [13].
Although the role of autophagy in melanoma is still controver-
sial, studies suggest that the dual function of autophagy also occurs
in melanomas. Key regulators of autophagy, autophagy-related
protein 5 (ATG5) and LC3B (microtubule-associated light chain
3B), is often down regulated in primary melanomas compared to
benign nevi [14,15]. Autophagy induction in benign nevi can
contribute to the establishment of oncogene-induced senescence
(e.g., driven by BRAFV600 expression), controlling melanocyte
proliferation. The protein Beclin-1 (BECN1) regulates one of the
first steps of autophagy and the first link between autophagy
and tumorigenesis was the discovery that Becn1+/ mice develops
spontaneous tumors [16], revealing a tumor-suppressor function of
autophagy. The identification that BECN1 binds anti-apoptotic
members of the BCL2 family, such as BCL2, BCL2L1/Bcl-xL and
MCL1, was the starting point to the correlation of apoptosis andautophagy [17]. However, it is questionable if BECN1 solely
accounts for tumor suppression. A study of patient-derived mela-
noma cells and tissue samples from benign nevi, primary and
metastatic melanomas showed a negative correlation of BECN1
and MCL1 with a mutual modulation of ubiquitination and
proteasomal degradation [18]. This work describes an autophagy-
independent function of BECN1 which contributes to tumor
suppression and the inverse co-regulation of BECN1 and MCL1
with a decrease of BECN1 and an increase in MCL1 associated with
melanoma progression.
In metastatic melanoma, autophagy is re-established as a pro-
survival mechanism to couple with metabolic demands and stress-
ful tumor microenvironment conditions [19–21], maintaining
energy production that can lead to tumor growth and therapeutic
resistance. Indeed, a high level of autophagy in tumors of mela-
noma patients is associated with a low therapeutic response and
a poor outcome [22]. These data indicate that autophagy is coupled
with melanoma progression, which motivated the search for anti-
melanoma therapeutic targets interfering with autophagy.
Phase I clinical trials indicated that blocking autophagy with
hydroxychloroquine (HCQ), which inhibits lysosome acidification,
is safe and tolerable. The combination of HCQ with alkylating
chemotherapy (temozolomide) [23] or an MTOR inhibitor (tem-
sirolimus) [24] had a significant antitumor activity in melanoma
patients. These data suggest that interfering with autophagy may
improve therapeutic effects of melanoma therapies; therefore, it
is necessary to consider the B-Raf status of melanomas. Treatment
of B-Raf wild-type melanoma cells with fenretinide or bortezomib
resulted in the activation of autophagy, in turn, in B-Raf-mutated
melanoma cells autophagy was significantly reduced, an effect
attributed partly to oncogenic B-Raf [25]. BRAFV600 melanoma
cells treated with B-Raf/MEK inhibitors resulted in cytoprotective
autophagy induction, and the autophagy inhibition enhanced
B-Raf inhibition-induced cell death [26]. Therefore, B-Raf mutant
status of melanoma patients interferes in the efficacy of
autophagy-blocking therapies. The combination of an autophagy
inhibitor with anticancer therapy can improve the outcome of
melanoma patients harboring wild type B-Raf. On the other hand,
autophagy inhibition may be effective only if combined with B-Raf
inhibitor in melanoma patients expressing BRAFV600.
Autophagy plays a crucial role in the maintenance of tumor cell
homeostasis during several stressing conditions, particularly in
endoplasmic reticulum (ER) stress [27]. Furthermore, autophagy
and ER stress are aberrantly increased in metastatic melanoma.
Treatment of BRAFV600 melanoma cells with the BRAFV600 inhi-
bitor, vemurafenib, induces autophagy and activates ER stress
[26]. Along these lines, there is growing evidence suggesting that
these two mechanisms are related with melanomagenesis and
chemoresistance.
2.2. Endoplasmic reticulum stress and the unfolded protein response
(UPR)
The endoplasmic reticulum (ER) is the organelle that forms an
interconnected network of tubules, vesicles, and cisternae within
cells. ER is an essential organelle in eukaryotic cells for calcium
storage, lipid biosynthesis and is responsible for protein folding,
translocation and post-translation modification. Approximately
one-third of the polypeptides synthesized by a cell enter the ER
where the polypeptides undergo different maturation steps
including folding, glycosylation, and disulfide bond formation to
enable protein achieves a distinct three-dimensional arrangement
[28,29]. The folding process depends on the high concentration of
calcium ions and oxidizing conditions of the ER lumen and on ER
resident protein chaperones. BiP/GRP78 is one of the most impor-
tant chaperones that facilitates the folding process through binding
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[30]. Another important family of proteins involved in the folding
machinery are the protein disulfide isomerases (PDI), a family of
oxidoreductases that catalyzes the formation of covalent bonds
between cysteine residues of a polypeptide [31]. After a high qual-
ity control system to assure that the protein is properly folded and
assembled, these proteins are packed into cytosolic coat protein II
(COPII)-derived vesicles and transported out of the ER to the Golgi
apparatus [32]. Only properly folded proteins exit the ER and move
on in the secretory pathway, improperly folded proteins are
retained in the ER and are targeted for proteasomal degradation,
a process called ER-associated degradation (ERAD) [33]. However,
changes in the cellular environment, such as alterations in
Ca2+ levels, redox state, nutrient status or increasing in the protein
synthesis rate, presence of pathogens and inflammatory stimuli
disrupt the ER protein-folding environment and lead to protein
misfolding or unfolded accumulation – a condition termed ER
stress.
The unfolded protein response (UPR) is activated in response
to accumulation of misfolded/unfolded proteins. UPR is a
collection of homeostatic signaling pathways that restores ER
function. UPR activation induces transient attenuation of protein
synthesis, increases protein trafficking through ER, increases
protein degradative pathways (ERAD) and induces autophagy. If
the ER stress is severe or persistent and these adaptive
mechanisms cannot resolve the protein-folding defect, cells enter
apoptosis. BiP/GRP78 has been referred to as the master regulator
of the ER because in addiction to participate in protein folding
process it also regulates the UPR induction. Misfolded proteins
bind to and sequester the chaperone BiP from three ER-resident
transmembrane proteins: IRE1 (inositol requiring enzyme 1),
PERK [double-stranded RNA-activated protein kinase (PKR)-like
ER kinase], and ATF6 (activating transcription factor 6). When
ER is in homeostasis, BiP is associated with these three trans-
membrane proteins; however, during ER stress BiP is recruited
to misfolded/unfolded proteins in an attempt to achieve the cor-
rectly protein fold [34]. The release of BiP activates ATF6, PERK,
and IRE1 resulting in the production of transcription factors that
enter in the nucleus and driver the transcription of UPR target
genes (Fig. 1).
The release of BiP from PERK, a type I transmembrane
protein, results in PERK homodimerization or oligomerization
and autophosphorylation, leading to its activation [35,36]. Once
activated, PERK then phosphorylates eIF2a (a subunit of the het-
erotrimeric eIF2 complex), attenuating the translation initiation
and reducing global protein synthesis and the influx of nascent
protein into the ER, enhancing the processing capacity of the ER
[37]. Concurrently, PERK also induces preferential translation of
stress-related transcripts, including that encoding activating
transcription factor 4 (ATF4 also known as CREB-2) [38]. The
transcription factor ATF4 activates ER stress response genes
involved in the antioxidant response and amino acid biosynthesis
and transport, favoring cell survival. CHOP (transcription factor
C/EBP homologous protein or GADD153) and GADD34 (growth
arrest and DNA damage-inducible 34) are two important genes
driven by ATF4. GADD34 dephosphorylates eIF2a during cellular
stresses, a negative feedback regulatory loop that promotes
translational recovery [39,40]. Whereas CHOP is a transcription
factor involved in cell cycle arrest and/or apoptosis [41] and one
of the mechanisms of CHOP-induced apoptosis is through the tran-
scriptional upregulation of several pro-apoptotic proteins of the
BCL-2 family, such as BIM [42] and the downregulation of the
pro-survival protein BCL-2 [43]. Additionally, eIF2a–ATF4 pathway
also elicits the transcriptional activation of genes involved in
regulating autophagy, the antioxidant response and amino acid
metabolism in response to stresses insults [44].Like PERK, IRE1a is a type I transmembrane protein with a
cytosolic serine/threonine kinase domain. Upon ER stress, BiP dis-
sociates from IRE1a liberating this protein for oligomerization and
autophosphorylation. In addition to a kinase domain, IRE1a has an
endoribonuclease domain and once activated, IRE1a cleaves X-box
binding protein 1 (Xbp1) mRNA creating a transcriptionally active
form (Xbp1s) that enters the nucleus to regulate target genes.
IRE1a–XBP1 regulates genes that increase protein folding,
trafficking and ERAD, promoting cell survival [45]. However,
hyperactivated IRE1a signals apoptosis by a process called regu-
lated IRE1-dependent decay (RIDD) that induces degradation of
mRNAs encoding growth-promoting proteins, thus leading to
increased cell death [46]. IRE1a also induces cell death by phos-
phorylation and activation of c-Jun N-terminal kinase (JNK) via for-
mation of complex with TRAF2 and activation of the apoptosis
signal-regulating kinase (ASK1).
ATF6 is a type II transmembrane protein and a member of the
ATF/CREB family of transcription factors. After dissociation from
BiP under ER stress, ATF6 traffics from the ER membrane to the
Golgi apparatus where it is sequentially cleaved by site-1 protease
(S1P) and S2P. ATF6 cleavage releases its cytoplasmic domain and
allows the ATF6 fragment (ATF6f) transcription factor to translo-
cate to the nucleus where it binds to ER-stress response elements
(ERSE) and induces transcription of several genes, including BiP,
CHOP and XBP1 to enter in the nucleus [47,48].
The three UPR branches, PERK, IRE1a and ATF6; co-regulate
most targets demonstrating the robustness of this adaptive
response that induce both adaptive and apoptotic responses to
ER stress. Roles for UPR in cancer were first proposed in 2004 by
Ma and Hendershot [49]. In cancer cells, particularly solid tumors,
the combination of rapid tumor growth and inadequate vascular-
ization result in microenvironmental stress such as hypoxia, nutri-
ent starvation, pH changes and oxidative stress that cause ER stress
and UPR activation [50]. These phenotypic alterations are a com-
mon feature of melanomas [7]. However, cancer cells can survive
despite the present of these stress insults. It is becoming increas-
ingly clear that cancer cells take advantage of the dual role of
UPR, enhancing pro-survival UPR signaling and reducing pro-
apoptotic signaling to assure cell survival and tumor growth. The
exposure to low levels of ER stress can induce hormesis, defined
as an adaptive response elicitated by low levels of stress that acti-
vates protective pathways and render cells resistant to a second
challenge with a higher dose of stress [51]. The ER hormesis was
first described in Drosophila with the observation that the loss of
ER protein induced a hormetic response resulting in resistance to
a secondary stressor, such as apoptotic insults or expression of
pathological proteins [52]. One example of ER hormesis in cancer
is that tumor cell survival is enhanced when expression of PERK
induced pro-apoptotic transcription factor CHOP is reduced
[53,54]. Nonetheless, cancer cells preserve PERK-mediated survival
signaling, such as Nrf2-dependent antioxidant responses [55] and
autophagy induction [56]. Another well-described survival mecha-
nism of tumor cells during ER stress is accumulation of chaperone
BiP that alleviates unfolded/misfolded protein accumulation and is
positively correlated with malignant cell proliferation and tumor
histologic grade [57]. Thus, the activation of UPR can either support
or repress tumorigenesis, depending on ER stress intensity or
chronicity and cellular context.
2.3. ER stress and melanoma
ER stress contributes to early stages of melanoma transforma-
tion but also to melanoma progression and chemoresistance. The
induction of UPR in melanocytes of nevus may control cell prolifer-
ation inducing cell cycle arrest and senescence. Nevus harboring
BRAFV600 or NRASQ61 mutation do not have increased risk of
Fig. 1. Under homeostasis, newly synthesized proteins in the ER are folded by the chaperones and post-translationally modified via acetylation, phosphorylation, methylation
or glycosylation into mature and functional proteins. Under stress conditions misfolded/unfolded proteins accumulate in ER lumen, a process termed ER stress, which
activates the unfolded protein response (UPR). The UPR pathway is mediated by three ER sensor proteins ATF6, PERK and IRE1a. These proteins are activated by the release of
the chaperone GRP78 recruited by the unfolded proteins accumulated in the ER. IRE1a activation induces the unconventional splicing of the transcription factor X-box
binding protein 1 (XBP1) mRNA, resulting in the expression of an active transcription factor (XBP1s) that upregulates a subset of adaptive UPR target genes encoding proteins
involved in folding machinery, ERAD process, protein quality control and phospholipid synthesis. IRE1 also induce a process known as regulated IRE1-dependent mRNA decay
(RIDD) interfering in the regulation of apoptosis. Once activated, PERK phosphorylates the eukaryotic translation initiator factor 2a (eIF2a) to attenuate general protein
synthesis, while favoring the selective translation of the ATF4 mRNA. ATF4 induces the expression of genes involved in restoring ER homeostasis such as antioxidant
responses, amino acid metabolism and autophagy, but also controls the expression of the pro-apoptotic component C/EBP-homologous protein (CHOP). During ER stress,
ATF6 translocates to the Golgi apparatus where it is cleaved releasing its cytosolic domain (ATF6f). ATF6f controls the upregulation of select UPR target genes. Autophagy
induction in response to ER stress is mediated by activation of ATF4, CHOP, XBP1 and JNK and serves as a cyto-protective or a cell death mechanism. Thus, mild ER stress
induces an ER protective response; however, during persistent or severe ER stress UPR triggers apoptosis. Abbreviations: ER, endoplasmic reticulum; ERAD, ER-associated
protein degradation; IRE1a, inositol-requiring enzyme 1a; PERK, protein kinase RNA-like ER kinase; ATF6, activating transcription factor 6.
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that prevents malignant transformation of melanocytes is the
‘‘oncogene-induced senescence” and the oncogene BRAFV600 is
one of the main suggested driver of this mechanism [59,60]. How-
ever, in melanocytes HRASG12V mutated, the induction of senes-
cence is mediated by ER stress and UPR pathway, but the same is
not observed in melanocytes harboring the oncogene BRAFV600
[61]. UPR can be tumor suppressive in early stages of melanoma
development but it also can be tumor promoting after melanoma
establishment.
ER stress can be detected not only in nevus, but also at early and
late stages of melanoma development which is evidenced by
GRP78 expression along melanoma progression [62,63]. In addi-
tion, melanoma cells in vitro have constitutive activation of UPR
with basal levels of CHOP expression [64] or sustained activation
of the IRE1a and ATF6 pathways [65]. Features of cancer cells, suchas increase in metabolic demand and high proliferation rates,
increase the demand for the secretory pathway requiring ER pro-
teostasis functions and consequently result in basal or constitutive
UPR activation.
At early stages ER stress limits nevus growth by senescence
induction and along melanoma progression the induction of UPR
indicates that these tumoral cells are coupling with ER stress.
The adaptation and selection of melanoma cells resistant to ER
stress may contribute to melanoma progression. In support of this,
melanoma cells are more resistant to ER stress-induced cell death
by classical ER stress inducer, tunicamycin or thapsigargin, than
melanocytes and fibroblasts [66], suggesting that melanoma cells
have developed protective mechanisms to survive under ER stress.
The RAS/RAF/MEK/ERK pathway plays a crucial role in melano-
mas once it is often mutated and constitutively activated in these
tumors, favoring melanoma proliferation and survival. Besides,
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resistance to ER stress. ER stress-induced cell death is character-
ized by rapid attenuation of the IRE1a and ATF6 pathways but
persistent activation of PERK signaling. However, in melanomas
MEK/ERK pathway contributes to sustained activation of IRE1a
and ATF6 along with the PERK signaling [65–67], favoring cell
survival despite the UPR cell death branch activation. Moreover,
the inhibition of MEK/ERK induce apoptosis of melanoma cells
in vitro by activation of caspase-4 [66] and caspase-8 [67], which
are inhibited by GRP78 and ARC, respectively. Besides, there is evi-
dence that the cell death induced by MEK/ERK pathway inhibition
it is also caspase-independent and mediated by the up-regulation/
activation of PUMA and Bim and down-regulation of Mcl-1 [68].
The antiapoptotic Bcl-2 family member Mcl-1 is another important
mechanism for melanoma survival during ER stress once Mcl-1
inhibition induces melanoma cell death mediated by Noxa and
Puma in response to ER stress induction [69,70]. In line with this,
ER stress activates multiple apoptosis pathways; however, they
are inhibited by various survival mechanisms, including activation
of MEK/ERK pathway, ARC or GRP78 expression; and Mcl-1 upreg-
ulation, in melanomas.
Inhibition of oncogenic BRAFV600 or MEK attenuated activation
of UPR in melanomas, revealing that the oncogenic activation of
MEK/ERK in addiction to promote proliferation also protects mela-
noma cells against apoptosis induced by acute ER stress [71]. Addi-
tionally, it was shown that the BRAFV600 kinase inhibitor
vemurafenib triggers ER stress which can be attributed for accu-
mulation of cytosolic calcium or sequestration of GRP78 by the
mutant B-Raf, and the acquired resistance to vemurafenib can be
overcomed by ER stress inducers or autophagy inhibition [26,72].
Additionally, the inhibition of the PDI activity increased the apop-
tosis in response to ER stress inducers, such as fenretinide and vel-
cade, in melanoma models. These data suggests that the utilization
of small-molecule PDI inhibitors can enhance the efficacy of
chemotherapy in melanomas [73]. Moreover, ER stress inducer
tunicamycin up-regulated death receptors for tumor necrosis fac-
tor (TNF)-related apoptosis-inducing ligand (TRAIL) in cell surface
of melanoma cells, sensitizing these cells to TRAIL induced cell
death. Although tunicamycin did not induced TRAIL expression in
normal cells, it was cytotoxic to these cells [64]. These data suggest
that the dose of ER stress inducer is crucial to allow for further
in vivo investigations.
In addition to control intracellular pathways, ER stress also
modulates the immune system. ER stress factors can be transferred
from tumor cells to myeloid cells, macrophages, and DCs, upregu-
lating both the production of proinflammatory cytokines, and the
immunosuppressive enzyme arginase [74]. As such, during tumor
growth, fluctuations in environmental variations induce UPR in
tumor cells that by ER stress-mediated signals, evade the host
immune system and progress toward tumorigenesis. It is also
important to note that the cell surface exposure of the ER-
resident chaperone calreticulin (CRT) is one of damage-associated
molecular patterns (DAMPs) associated with immunogenic cell
death (ICD) [75]. Moreover, ecto-CRT in cancer cells undergoing
ICD in response to anthracyclines, facilitates their engulfment by
dendritic cells, which leads to tumor antigen presentation and
tumor-specific cytotoxic T lymphocyte (CTL) responses [76]. Differ-
ently from anthracyclines, cisplatin (CDDP) fails to induce
immunogenic tumor cell death and this can be in part due to the
absence of cell surface exposure of CRT in response to CDDP treat-
ment. However, the combination of ER stress inducers and CDDP
resulted in the translocation of CRT to the plasma membrane, as
well as immunogenic cell death, although the ER stress inducer
tunicamycin or CDDP alone were insufficient to result in the CRT
exposure and immunogenic cell death [77]. These data illustrate
that ER stress has an important contribution to the immunogenic-ity of cell death of cancer cells. Additionally, UPR also modulates
angiogenesis; through the ATF4 pathway, which mediates the
transcription of VEGF during ER stress [78]. The secretion of newly
translated VEGF is controlled by the ER-localized chaperone
GRP170 [79].
Altogether, the activation of cellular stress responses mediated
by the ER stress confers advantages to cancer cells and allows these
cells to survive in unfavorable environment conditions. As
described above, UPR pathway can engage both pro-survival and
pro-apoptotic cellular programs. In addition, UPR pathway is fre-
quently chronically activated in tumor cells, differently from
non-stressed normal cells. Thus, interfering in signaling pathways
that result in cancer cells protection against ER stress is one of
the therapeutic strategies that have been investigated to treat
cancer. There are two main strategies to modulate UPR signaling:
inhibiting UPR pro-survival effects or aggravating the pre-
existing stress in tumor cells to surpass the adapted levels to ER
stress and force cells to switch to a pro-apoptotic response. There
are available chemical compounds with potential to intervene in
key mediators of ER stress signaling that are into preclinical or clin-
ical studies, reviewed in [80,81]. However, so far, there is no one
approved treatment based on UPR pathway modulation. Indeed,
the challenge issue of UPR-mediated therapeutic strategy is the
adjustment of drug concentrations and regimens to avoid toxicity
in normal cells and side effects in clinical trials. The experimental
and preclinical data demonstrate that targeting UPR signaling is a
potential strategy to treat tumors; however, more studies are
needed to define UPR components and mechanisms that
fine-tune the UPR, allowing the prediction of side effects. UPR,
autophagy and proteasomal degradation are essential mechanisms
to maintain cellular homeostasis and survival by degradation and
recycling of damaged proteins. Novel drugs that interfere with pro-
teasomal activity and simultaneously induce UPR signaling are
promising antimelanoma agents, such as Amblyomin-X, a protease
inhibitor predicted by reverse engineering from the genome of the
tick Amblyomma cajennense [82,83] and 4-nerolidylcatechol, a nat-
ural product extracted from Pothomorphe umbellate [84].
2.4. Altered melanoma metabolism
Along melanoma progression, different subpopulations of can-
cer cells are found within the very same tumor. Failure in treating
melanoma with targeted agents, such as vemurafenib e.g., may
reside in the heterogeneity of cellular populations, which already
exist in a given tumor when therapy starts. Therefore,
chemotherapy-induced stress in melanoma cells can select for a
resistant phenotype. Furthermore, there is increasing evidence that
treatment itself can also induce epigenetic changes reprogram-
ming cells, leading to the generation of tumor cell subpopulations
that in turn favor melanoma survival. [85]. One of these subpopu-
lations is characterized by the overexpression of the histone
demethylase JARID1b (KDM5B/PLU-1/RBP2-H1). During melanoma
development, JARID1b expression is progressively downregulated.
In benign melanocytic nevi, 70% of the cases have high expression
of JARID1b. During tumor progression, 90% of the primary malig-
nant melanomas have low expression of JARID1b and 70% of the
metastatic melanomas have also low expression of JARID1b [86].
Even in melanomas with low expression of JARID1b, some positive
cells can be seen, as a small subpopulation of the main tumor.
Different therapeutic strategies select for the JARID1b positive
subpopulation. Cisplatin and vemurafenib enrich this subpopula-
tion in melanoma cell lines as well in animal model. Other drugs,
like bortezomib and temozolomide have similar effects. This sub-
population is strongly chemoresistant. Knock-down of JARID1b
can restore melanoma sensitivity of JARID1b-highly positive (high)
cells against bortezomib and vemurafenib in xenotransplanted
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low cells, changing dramatically their behavior [87]. The JARID1b
positive melanoma subpopulation is slow-cycling. Such feature is
at least partly explained through JARID1b interaction with the
retinoblastoma (Rb) protein. When in complex with the transcrip-
tion factor E2F, Rb recruits JARID1b to modify the chromatin struc-
ture of E2F target genes, to repress their transcription [88]. As E2F
transcription factor family is strongly related to cell cycle progres-
sion, cells with high JARID1b expression will repress entrance of
cells into the cell cycle. Therefore, JARID1b-high populations tend
to resist to genotoxic therapies.
In terms of metabolism, the JARID1b-high subpopulation of
melanomas is different than what is expected for a dividing tumor
cell, as it is dependent on oxidative phosphorylation and not aero-
bic glycolysis (Warburg effect). Many mitochondrial proteins,
related to bioenergetic metabolism accumulate in JARID1b-high
cells and many of these proteins are related to the cell respiratory
electron transport chain, like nicotinamide adenine dinucleotide
(NADH) dehydrogenase, which is part of the complex I of the mito-
chondrial electron transport chain, ubiquinol cytochrome c reduc-
tase, which is part of the complex III, cytochrome c oxidase, which
is part of the complex IV. On the other hand, some components of
the glycolytic pathway are down-regulated in JARID1b-high cells,
like hexokinases I and II [87].
This differential expression pattern of metabolic enzymes is
associated with increased efficiency of mitochondria in JARID1b-
high melanoma cells, as compared to the JARID1b-low cells. Their
mitochondria also consume more oxygen and produce more H2O2
than the mitochondria of the JARID1b-low cells. This behavior sug-
gests that the JARID1b cells may need a redox signaling activated,
because they can suffer injuries from the excess of ROS released by
the active mitochondria.
The use of drugs that shift the oxidative metabolism of JARID1b-
high cells to glycolysis can sensitize JARID1b-high cells to death.
The idea of this strategy is to turn off cellular adaptations to ROS.
This is achieved, for example, through the use of phenformin (an
AMPK activator). Together, phenformin and PLX4720 can decrease
the tumor volume of BRAFV600melanoma cells in mice xenografts.
The combination of the two drugs can act in different populations.
While PLX4720 induces JARID1b-low cells to death, phenformin
sensitizes death of the JARID1b-high cells [89] (summarized in
Fig. 2). Recently, the prooxidant copper-chelator elesclomol was
able to kill the JARID1b-high subpopulation through an imbalanceFig. 2. Jarid1b induces chemoresistance through cell cycle inhibition and through a
metabolic shift from glycolysis to oxidative phosphorylation.of ROS production. This latter strategy could be used together with
drugs that also induce ROS to exceed the threshold of ROS adapta-
tion in melanoma cells [90]. Altogether, the JARID1b subpopulation
can be responsible for melanoma repopulation after chemother-
apy. After treatment, surviving JARID1b-high cells turn into
JARID1b-low cells, which proliferate faster than the JARID1b-high
cells, increasing tumor mass and leading to treatment failure [91].
Another subpopulation of melanoma cells is characterized by
the expression of the transcriptional coactivator PGC1a. This coac-
tivator is responsible for mitochondrial biogenesis and therefore it
is a regulator of mitochondrial mass, thermogenic programs and
adaptation to fasting conditions [92]. Usually, PGC1a expression
is low within any tissue but when there is a need for high meta-
bolic or energetic demand, PGC1a expression is strongly increased.
PGC1a-high cells express different mitochondrial genes related to
oxidative phosphorylation. Transcription of mitochondrial proteins
of the complex I, III, IV and V depends on PGC1a. The increase of
mitochondrial mass by PGC1a shifts tumor cell metabolism to
oxidative phosphorylation. Like JARID1b-high cells, PGC1a-high
cells produce more ATP, less lactate and are more resistant to geno-
toxic chemotherapeutic agents than PGC1a-low cells [93]. Antiox-
idant defenses are also higher in PGC1a-high cells, which
accumulate both SOD2 and GSH [93].
BRAFV600 melanomas have the MAPK pathway activated, and
this mutation seems to regulate the metabolism of these cells.
Treatment with the vemurafenib precursor PLX4720 induces mito-
chondriogenesis and a decrease in lactate production through sup-
pression of MITF activity, an oncogenic melanocyte lineage-
specification transcription factor that regulates PGC1a expression.
Cells treated with PLX4720 have high levels of mitochondria
oxidative phosphorylation [94]. At least for BRAFV600 melanoma
cells, vemurafenib treatment not only activates alternative
pathways for MAPK activation which helps tumor survival and
proliferation but also changes the metabolic behavior of these cells,
helping to improve tumor survival. Besides inducing mitochondria
biogenesis, PGC1a can change the cell metabolism by HIF1a
suppression, thus decreasing transcription of genes coding for
glycolytic enzymes. On the other hand, downregulation of PGC1a
leads to HIF1a stabilization through ROS signaling, inducing a shift
to glycolysis in melanomas [95]. In terms of treatment, one
strategy to overcome chemotherapy resistance induced by PGC1a
is to target the mTor pathway. For example, the inhibition of
mTorc1/2 by AZD8055 was able to sensitize melanoma cells with
high levels of oxidative phosphorylation to the MEK inhibitor
selumetinib by downregulation of PGC1a expression in melanoma
cells [96].
The coexistence of distinct subpopulations within melanomas,
illustrated by the JARID1b and the PGC1a-positive subpopulations
discussed above highlights the complexity of treating melanoma
and the importance of evaluating the treatment responses as a pro-
cess of evolutionary dynamics. Such heterogeneity calls for a
greater precision in defining the composition of the tumor mass
as targetable units, and imply timely combination therapy strate-
gies to control the disease.
3. Extrinsic mechanisms for chemoresistance and tumor
repopulation
3.1. Phoenix Rising
Currently, melanoma patients are submitted to treatments such
as chemotherapy and targeted therapies. These treatments are
administered periodically and in multiple doses to ensure the
recovery of normal tissues during therapeutic window. Neverthe-
less, the surviving tumor cells are also able to proliferate during
these intervals and could lead to tumor repopulation. Clinically,
3444 R.F. Saito et al. / FEBS Letters 589 (2015) 3438–3448this process is known as recurrence and can occur where the pri-
mary tumor originated (local recurrence), in the surrounding tis-
sue, potentially affecting lymph nodes (regional recurrence) or in
other organs distant from the primary tumor (metastatic
recurrence). Irrespective of the recurrence type, the repopulation
phenomenon has a negative impact on treatment [97].
In local recurrence, tumor cells that are resistant to treatment
survive and continue to proliferate, leading to subsequent tumor
growth. A similar process occurs physiologically during wound
healing and tissue regeneration. Initially, immune cells were
thought to be the first to participate in this process, playing a cru-
cial role in initiating and coordinating the biological responses of
wound healing. Conversely, studies indicated no alteration in
wound healing in mice lacking macrophages and neutrophils
[98]. Although the cellular and molecular events involved in this
process remain unclear, it is known that factors released by dam-
aged tissues recruit cells to replace them. These replacement cells
may be stem cells (from injured tissue or its surroundings) and
progenitor cells, which are capable of proliferate and differentiate,
consequently recovering any damage. Contrary to what was
initially thought, the signaling to cell repopulation in the wound
healing process is not exclusively dependent on released factors
from immune cells, but also from factors originated by apoptotic
cells present at the injury site [99].
During cytotoxic cancer treatments, part of the tumor cells trig-
ger apoptosis and immune cells with scavenger receptors are
recruited to remove these cells from the microenvironment, ensur-
ing tissue homeostasis [100]. Nonetheless, some cells from the
heterogeneous tumor mass are resistant to cell damage proceeding
from these cytotoxic treatments. Thus, such as the wound healing
process, the apoptotic cells could release growth stimuli to other
cells, culminating in tumor repopulation [101,102] and thus treat-
ment failure. Mechanisms underlying tumor repopulation are
emerging as novel targets for combination therapy.
3.2. PAF as a novel mediator of the Phoenix Rising model
While the molecular mechanisms involved in tumor repopula-
tion are not extensively elucidated in literature, the study from
Li’s group [102] revealed that cells undergoing apoptosis during
radiotherapy or chemotherapy provide proliferative signals to the
surviving cells in a process that depends on the activation of cas-
pase 3. This process has become known as Phoenix Rising, alluding
to the mythological bird which rises alive from ashes, and it reveals
a new function for caspase 3: the ability to contribute to cell sur-
vival. According to the Phoenix Rising model, caspase 3 not only
activates apoptosis, but also leads to the activation of phospholi-
pase A2 (pLA2), which in turn produces arachidonic acid (AA).
Under cyclooxygenase 2 (COX 2) activity, AA is transformed into
prostaglandin H2 (PGH2) that is finally converted in prostaglandin
E2 (PGE2) by prostaglandin E synthase (PGES). PGE2 plays a crucial
role in cell proliferation and is essential for tumor repopulation
[101,102].
In addition to the production of PGE2, activation of pLA2 leads
to the accumulation of the precursor of platelet activating factor,
PAF [101] (Fig. 3). The role of PAF occurs through its receptor, PAFR,
a seven transmembrane-spanning G protein coupled receptor, pre-
sent in responsive cells, e.g., macrophages, neutrophils, endothelial
cells, keratinocytes and tumor cells [103]. Recent experiments
have related PAF and chemotherapy demonstrating that PAFR,
through a mechanism dependent on NF-kB, can increase the pro-
duction of pro-inflammatory cytokines, as IL-8 and TNF-a, in
response to treatment in a human epithelial carcinoma cell line
[104]. In a melanoma cell line, PAF induces up-regulation of anti-
apoptotic factors, such Bcl2 and Bcl-x, in a NF-kB-dependent man-
ner, suggesting that PAF may decrease the cytotoxic effect ofchemotherapeutic agents, therefore, contributing to cell survival
[105].
There is also evidence that chemotherapy induces the produc-
tion of PAFR agonists which are mostly generated nonenzymati-
cally and favor immunosuppression in melanoma cells and that
in vivo chemotherapeutic administration increases tumor growth
in a PAFR-dependent process. Intriguingly the treatment itself
leads to the production of factors that limit its efficacy. Combina-
tion strategies, including the use of antioxidants, COX-2 inhibitors
or depletion of Tregs improved treatment effectiveness [106].
Besides that, we have shown that cisplatin induces an increase in
PAFR expression in a human melanoma cell line. In this work the
combination therapy using cisplatin and a PAFR antagonist, WEB
2086, reduced the tumor volume and caused a higher tumor
regression when compared to each treatment alone. These data
reinforce the idea that the activation of PAFR pathway favors sur-
vival. Interestingly, differential effects observed in vivo and
in vitro, indicate that heterotypic interactions (between tumor
and microenvironmental cells) are PAFR-dependent [107]. Similar
results were also observed with another chemotherapeutic agent,
dacarbazine [108].
Phagocytosis of apoptotic cells by macrophages is known to
induce their polarization towards a suppressive phenotype [109].
This process is particularly relevant in tumors, since immunosup-
pression favors tumor growth. In fact, studies have shown that in
a melanoma model, the co-injection of a large number of apoptotic
cells can promote tumor growth from a subtumorigenic dose of
melanoma cells and this combination induces an inflammatory
response, recruiting neutrophils and macrophages [110]. Further
studies have related that this process is in part mediated by PAFR
[108,111]. Besides, the suppressive phenotype of macrophages
induced by the clearance of apoptotic cells depends on PAFR and
CD36 expressed by macrophages [112,113]. PAF signaling also
modulate dendritic cell differentiation through potentiation of IL-
10 and PGE2 production [114]. These data suggest that lipid medi-
ators are involved in immunosuppression and consequently, tumor
growth. These immunoregulatory molecules are in part trans-
ported by tumor-derived extracellular vesicles, which play an
important role in intercellular communication, favoring metastasis
in a phosphatydilserine-dependent manner [115,116].
3.3. Shed extracellular vesicles and tumor spreading
All cells secrete a variety of vesicles (extracellular vesicles)
under physiological and pathological conditions. Microvesicles
and exosomes are the most commonly studied ones and they differ
mainly from size and contents. Microvesicles range between 100
and 1000 nm in diameter, whereas exosomes are smaller and
range between 50 and 100 nm. Cells release microvesicles to the
extracellular space by outward budding of plasma membrane,
whereas exosomes are formed through invagination of the plasma
membrane into endosomes and then are released into extracellular
space as reviewed elsewhere [117,118] (Fig. 4). Another important
difference between microvesicles and exosomes is in their protein
composition. While microvesicles contain beta1-integrin, metallo-
proteases, glycoproteins and P-selectins, exosomes contain Alix,
TSG101, Hsp70 and tetraspanins as CD63, CD81 and CD9 [119].
Accumulating evidence indicate that exosomes play an impor-
tant role in intercellular communication. Exosomes can carry and
transfer protein, mRNA and miRNA into other cells. Several biolog-
ical functions have been addressed to exosomes including immune
regulation, protein and genetic intercellular exchange and modula-
tion of therapy response [120–123]. Many of these functions have
an important role in melanoma progression. Transfer of oncogenes
may modulate the activity of cellular signaling pathways and play
decisive roles in tumor growth and metastasis. Recently data have
Fig. 3. Scheme of molecular events involved in tumor cell repopulation after cytotoxic treatment observed clinically as tumor recurrence.
Fig. 4. Cells release microvesicles to the extracellular space by outward budding of plasma membrane, whereas exosomes are formed through invagination of the plasma
membrane into early endosomes and then are released by fusion of MVEs with the plasma membrane. Some MVB fuse with lysosomes to degradation. Membrane-associated
proteins on vesicles are represented as yellow triangles and orange spots. Cell on rectangle represent mechanism of release of extracellular vesicles (EVs) by cells into
microenvironment tumor.
R.F. Saito et al. / FEBS Letters 589 (2015) 3438–3448 3445showed that Wnt5a induces release of exosomes containing
pro-angiogenic and immunosuppressive factors from malignant
melanoma cells [124]. Exosomes released by melanoma cells can
also impair macrophage and dendritic cell functions, which may
contribute to anti-tumor immune response [125]. Moreover, exo-somes can carry other molecules that contribute to tumor resis-
tance modulating response to therapy. Federici et al. has recently
shown that cisplatin can be carried by exosomes in resistant cells.
Exosomes may be then used by cells to extrude drugs to the
extracellular space, thus detoxifiying the tumor cells [126].
3446 R.F. Saito et al. / FEBS Letters 589 (2015) 3438–3448Exosomes are secreted to prepare metastatic niches (reviewed
in [127]). Exosomes released by melanoma cells prepare sentinel
lymph nodes for tumor metastasis, as melanoma cells preferen-
tially migrate towards tissues modified by melanoma-derived exo-
somes [128]. Hao et al. found that exosomes isolated from highly
metastatic melanoma BL6-F10 cells carry the metastatic pheno-
type and can transfer it into poorly metastatic F1 melanoma cells.
These data have shown the role of exosomes in reprogramming
recipient cells to a more aggressive phenotype. Exosomes from
melanoma cells can transfer proteins and microRNA to multiple
cell types, including fibroblasts, endothelial cells and bone marrow
progenitor cells, then contributing to the generation of metastatic
microenvironments. Exosomes from highly metastatic melanomas
increased the metastatic behavior of primary tumors by directing
bone marrow progenitors through the receptor tyrosine kinase
MET [129]. Webber et al. found that tumor exosomes modulate
fibroblast phenotype and functions via exosomal TGF-beta that
also promotes the differentiation of fibroblasts into myofibroblasts,
which support tumor growth, vascularization and metastasis. In
fact, tumor extracellular vesicles increased TGF-beta1 production
by macrophages [116], besides enhancing the metastatic potential
of murine melanoma cells in a tissue factor dependent manner
[130]. As pointed above, extracellular vesicles are also efficient car-
riers of lipid-derived molecules, such as PAF and PAF-like mole-
cules which signal through specific receptors expressed by a
variety of microenvironmental cells.
4. Conclusions and perspectives
Emergence of treatment resistance is a critical issue in the man-
agement of cancer patients. Resistant cancer cells are progressively
selected for their genomic instability and capacity to survive in
extreme microenvironment conditions. Melanomas comprise an
interesting model to understand how tumor cells adapt to survive,
reprogram their metabolic pattern and communicate while dying,
through extracellular vesicles shed to distant sites and eventually
preparing the soil (tissular niches) for surviving cells. Such features
also provide a platform of varied targets for combination therapy,
which can improve treatment efficacy if used in a timely manner.
Autophagy, adaptation to endoplasmic reticulum stress, metabolic
reprogramming and tumor repopulation, through extracellular
vesicle signaling, are emerging processes that can be targeted.
Novel drugs interfering with these processes may allow for revisit-
ing conventional chemotherapy for melanoma patients, a practi-
cally abandoned alternative in high income countries, but often
used (suboptimally) for melanoma patients in low and middle
income countries. These strategies are also promising in combina-
tion with both targeted therapies and immunotherapies, which are
gaining momentum in melanoma patient management.
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